​

NewcelX Stock (NASDAQ:NCEL)

OwnershipFinancialsChart
NewcelX by TradingView

Previous Close

$3.59

52W Range

$1.83 - $30.80

50D Avg

$3.37

200D Avg

$5.93

Market Cap

$1.60M

Avg Vol (3M)

$53.28K

Beta

0.93

Div Yield

-

NCEL Company Profile

NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CH

Employees

11

IPO Date

Oct 24, 2025

Website

NCEL Performance

NCEL Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-4.38M$-11.81M$-15.48M
Net Income$-1.98M$-12.17M$-16.50M
EBITDA$-3.63M$-11.80M$-15.47M
Basic EPS$-26.30$-3.20$-8.40
Diluted EPS$-26.30$-3.20$-8.40

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
OCEAOcean Biomedical, Inc.
SRZNSurrozen, Inc.
CELUCelularity Inc.
PREPrenetics Global Limited
CEROCERo Therapeutics Holdings, Inc.
BACKIMAC Holdings, Inc.
SABSSAB Biotherapeutics, Inc.
NUWENuwellis, Inc.
KTTAPasithea Therapeutics Corp.